✦ LIBER ✦

T cells armed with anti-CD3 × anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro

✍ Scribed by Jonathan M. Gall; Pamela A. Davol; Ryan C. Grabert; Mark Deaver; Lawrence G. Lum

Book ID: 113615920
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 317 KB
Volume: 33
Category: Article
ISSN: 0301-472X
DOI: 10.1016/j.exphem.2005.01.007

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Bi20 (fBTA05), a novel trifunctional bis

Bi20 (fBTA05), a novel trifunctional bispecific antibody (anti-CD20 × anti-CD3), mediates efficient killing of B-cell lymphoma cells even with very low CD20 expression levels

✍ Michael Stanglmaier; Margot Faltin; Peter Ruf; Annette Bodenhausen; Petra Schröd 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 312 KB

## Abstract Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti‐CD20 × anti‐CD3), that connects B cells and T cells __via__ its variab

In vitro Cytolysis of B-Lymphoma Cells M

In vitro Cytolysis of B-Lymphoma Cells Mediated by an Anti-CD3/Anti-CD20 Bispecific Single-chain Antibody

✍ YU, R; LI, S; WU, B; LIU, H; YE, L; LIU, X; WANG, Q; CHEN, Z 📂 Article 📅 2006 🏛 Elsevier Science ⚖ 872 KB

Activated T cells from umbilical cord bl

Activated T cells from umbilical cord blood armed with anti-CD3 × anti-CD20 bispecific antibody mediate specific cytotoxicity against CD20+ targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants

✍ Archana Thakur; Carly Sorenson; Oxana Norkina; Dana Schalk; Voravit Ratanatharat 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 922 KB

Targeting Myeloma Stem Cells with T Cell

Targeting Myeloma Stem Cells with T Cells Armed with Anti-CD3 X Anti-CD20 Bispecific Antibody (CD20BI) Prior to ASCT Leads to Development of Anti-Myeloma Immune Responses Post Autologous Stem Cell Transplant That Can Be Boosted with Targeted T Cells

✍ L.G. Lawrence; T. Archana; A. Muneer; A.-K. Zaid; R. Voravit; Z. Jeffrey; A. Loi 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 57 KB

Immunotherapy of recurrent B-cell malign

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

✍ Buhmann, R; Simoes, B; Stanglmaier, M; Yang, T; Faltin, M; Bund, D; Lindhofer, H 📂 Article 📅 2008 🏛 Nature Publishing Group 🌐 English ⚖ 278 KB

Overcoming bortezomib resistance in huma

Overcoming bortezomib resistance in human B cells by anti-CD20/rituximab-mediated complement-dependent cytotoxicity and epoxyketone-based irreversible proteasome inhibitors

✍ Sue Ellen Verbrugge,Marjon Al,Yehuda G Assaraf… 📂 Article 📅 2013 🏛 BioMed Central 🌐 English ⚖ 446 KB